Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18224 | 0.80 | CYP3A4 (1.00) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL21695780 | 0.79 | GAA (0.50) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL28015082 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL11020186 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Iodide SCHEMBL28328087 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Hydrogen Sulfide SCHEMBL27992646 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL10546483 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL4340169 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL29858952 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL11020188 | 0.77 | CYP3A4 (0.93) | CYP3A4TSHRTDP1GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20170227545-A1 | REACTIVITY-BASED SCREENING FOR NATURAL PRODUCT DISCOVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-08-10 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-06-29 | — | — | US | disclosed |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-06-29 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| EP-0785927-A4 | NOVEL BENZOXAZOLES | EURO CELTIQUE SA (LU) | 1997-12-29 | — | — | EP | disclosed |
| EP-0785927-A1 | NOVEL BENZOXAZOLES | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011917-A1 | NOVEL BENZOXAZOLES | EURO-CELTIQUE, S.A. (LU) | 1996-04-25 | — | — | WO | disclosed |
| EP-0136745-B1 | BENZOYL UREA DERIVATIVES HAVING ANTI-TUMOR ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-06-07 | — | — | EP | disclosed |
| US-4716204-A | ADDUCTS OF BENZO-N-HETEROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| US-4701512-A | DIISOCYANATE-BLOCKING AGENT RELEASED BY HEATING AND CONVERTED INTO AN EPOXIDE-CROSSLINKER | THE DOW CHEMICAL COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4631331-A | BENZO-N-HETEROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4631332-A | Use of benzo-n-heterocycles to advance epoxy resins | THE DOW CHEMICAL COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0136745-A2 | Benzoyl urea derivatives having anti-tumor activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1985-04-10 | — | — | EP | disclosed |
| US-4110116-A | Fogged direct positive silver halide emulsion containing a cyanine dye having at least one benzoxazole or benzothiazole nucleus substituted with halogen atoms | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CYP3A4 4167/4885TSHR 3560/4885TDP1 1433/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CYP3A4 4167/4885TSHR 3560/4885TDP1 1433/4885 |
| US-20170227545-A1 | REACTIVITY-BASED SCREENING FOR NATURAL PRODUCT DISCOVERY | NQO1, NCL, NANS | CYP3A4 476/4885TSHR 4081/4885TDP1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.